Can personalized use of nsaids be a reality in the clinic?

The use of NSAIDs in rheumatology could be improved by an appropriate risk scoring system that accounts for adverse events such as bleeding and thrombosis. Such a risk score has now been

developed using data from the PRECISION trial, but is this score ready to be applied in clinical practice? Access through your institution Buy or subscribe This is a preview of subscription

content, access via your institution ACCESS OPTIONS Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access

subscription $29.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this

article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in

* Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Nissen, S. E. et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for

arthritis. _N. Engl. J. Med._ 375, 2519–2529 (2016). Article  CAS  Google Scholar  * Solomon, D. H. et al. Validation of a major toxicity risk score among NSAID users based on data from a

randomized controlled trial. _Arthritis Rheumatol._ https://doi.org/10.1002/art.40870 (2019). Article  PubMed  Google Scholar  * Gunaydin, C. & Bilge, S. S. Effects of nonsteroidal

anti-inflammatory drugs at the molecular level. _Eurasian J. Med._ 50, 116–121 (2018). Article  Google Scholar  * Bombardier, C. et al. Comparison of upper gastrointestinal toxicity of

rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. _N. Engl. J. Med._ 343, 1520–1528 (2000). Article  CAS  Google Scholar  * Silverstein, F. E. et al.

Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib

long-term arthritis safety study. _JAMA_ 284, 1247–1255 (2000). Article  CAS  Google Scholar  * Schnitzer, T. J. et al. Comparison of lumiracoxib with naproxen and ibuprofen in the

therapeutics arthritis research and gastrointestinal event trial (TARGET), reduction in ulcer complications: randomised control trial. _Lancet_ 364, 665–674 (2004). Article  CAS  Google

Scholar  * Trelle, S. et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. _BMJ_ 342, c7086 (2001). Article  Google Scholar  * US Food and Drug

Administration. Nonsteroidal anti-inflammatory drugs (NSAIDs). _FDA_ https://www.fda.gov/Drugs/DrugSafety/ucm103420.htm (updated 10 May 2016). * European Medicines Agency. PRAC recommends

the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors. _EMA_

https://www.ema.europa.eu/en/news/prac-recommends-same-cardiovascular-precautions-diclofenac-selective-cox-2-inhibitors (2013). * Kanis, J. A. et al. FRAX and the assessment of fracture

probability in men and women from the UK. _Osteoporos. Int._ 19, 385–397 (2008). Article  CAS  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Amsterdam

Rheumatology & Immunology Centre: Amsterdam UMC–Vrije Universiteit Amsterdam & Reade Rheumatology, Amsterdam, Netherlands Michael T. Nurmohamed Authors * Michael T. Nurmohamed View

author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Michael T. Nurmohamed. ETHICS DECLARATIONS COMPETING INTERESTS M.T.N.

declares he has received research support and lecture fees from Abbvie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi and UCB;

and has been on the advisory boards for Abbvie, Biogen, Bristol-Myers Squibb, Celgene, Celltrion, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi and UCB. RIGHTS

AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Nurmohamed, M.T. Can personalized use of NSAIDs be a reality in the clinic?. _Nat Rev Rheumatol_ 15, 387–388

(2019). https://doi.org/10.1038/s41584-019-0225-7 Download citation * Published: 30 April 2019 * Issue Date: July 2019 * DOI: https://doi.org/10.1038/s41584-019-0225-7 SHARE THIS ARTICLE

Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided

by the Springer Nature SharedIt content-sharing initiative